ATE335501T1 - Mittel zur behandlung von allergischen oder überempfindlichkeitszuständen - Google Patents
Mittel zur behandlung von allergischen oder überempfindlichkeitszuständenInfo
- Publication number
- ATE335501T1 ATE335501T1 AT99900567T AT99900567T ATE335501T1 AT E335501 T1 ATE335501 T1 AT E335501T1 AT 99900567 T AT99900567 T AT 99900567T AT 99900567 T AT99900567 T AT 99900567T AT E335501 T1 ATE335501 T1 AT E335501T1
- Authority
- AT
- Austria
- Prior art keywords
- allergic
- agents
- treatment
- hypersensitivity
- hypersensitivity conditions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9800487.2A GB9800487D0 (en) | 1998-01-09 | 1998-01-09 | Therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE335501T1 true ATE335501T1 (de) | 2006-09-15 |
Family
ID=10825085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99900567T ATE335501T1 (de) | 1998-01-09 | 1999-01-08 | Mittel zur behandlung von allergischen oder überempfindlichkeitszuständen |
Country Status (14)
Country | Link |
---|---|
US (4) | US7208155B1 (de) |
EP (2) | EP1044014B9 (de) |
JP (5) | JP2002500194A (de) |
AT (1) | ATE335501T1 (de) |
AU (1) | AU762478B2 (de) |
CA (1) | CA2317443C (de) |
CY (1) | CY1105651T1 (de) |
DE (1) | DE69932702T2 (de) |
DK (1) | DK1044014T3 (de) |
ES (1) | ES2270575T3 (de) |
GB (2) | GB9800487D0 (de) |
NZ (1) | NZ526218A (de) |
PT (1) | PT1044014E (de) |
WO (1) | WO1999034817A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9800487D0 (en) | 1998-01-09 | 1998-03-04 | Oratol Limited | Therapies |
DK1964570T3 (da) | 2007-03-02 | 2012-12-17 | Protectimmun Gmbh | Farmaceutisk sammensætning til beskyttelse mod allergier og inflammatoriske sygdomme |
US20120128597A1 (en) * | 2008-08-16 | 2012-05-24 | Forschungszentrum Borstel | Composition for prevention and treatment of allergic and/or inflammatory diseases |
US8241608B2 (en) * | 2010-03-23 | 2012-08-14 | Development Center For Biotechnology | Treating allergy with detoxified E. coli heat-labile enterotoxin |
WO2012049312A1 (en) * | 2010-10-15 | 2012-04-19 | Alk-Abelló A/S | Suppression of a type 1 hypersensitivity immune response with an unrelated antigen |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614611A (en) | 1987-12-31 | 1997-03-25 | Tanox Biosystems, Inc. | Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils |
WO1991012818A1 (en) | 1990-02-23 | 1991-09-05 | Immulogic Pharmaceutical Corporation | Superantigen induced immune non-responsiveness |
US5681571A (en) * | 1993-10-08 | 1997-10-28 | Duotol Ab | Immunological tolerance-inducing agent |
DE4430041A1 (de) * | 1994-08-24 | 1996-02-29 | Milupa Ag | Allergieprotektive Formelnahrung |
GB9513733D0 (en) * | 1995-07-05 | 1995-09-06 | Univ Bristol | Therapeutic agents |
US20010036917A1 (en) * | 1995-07-05 | 2001-11-01 | Williams Neil Andrew | Therapeutic agents |
US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US7097845B2 (en) | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
GB9800487D0 (en) * | 1998-01-09 | 1998-03-04 | Oratol Limited | Therapies |
GB9819484D0 (en) * | 1998-09-07 | 1998-10-28 | Univ Bristol | Therapeutic agents |
-
1998
- 1998-01-09 GB GBGB9800487.2A patent/GB9800487D0/en not_active Ceased
-
1999
- 1999-01-08 CA CA002317443A patent/CA2317443C/en not_active Expired - Fee Related
- 1999-01-08 US US09/600,060 patent/US7208155B1/en not_active Expired - Fee Related
- 1999-01-08 AU AU19782/99A patent/AU762478B2/en not_active Ceased
- 1999-01-08 WO PCT/GB1999/000070 patent/WO1999034817A1/en active IP Right Grant
- 1999-01-08 DK DK99900567T patent/DK1044014T3/da active
- 1999-01-08 EP EP99900567A patent/EP1044014B9/de not_active Expired - Lifetime
- 1999-01-08 JP JP2000527265A patent/JP2002500194A/ja not_active Withdrawn
- 1999-01-08 NZ NZ526218A patent/NZ526218A/en not_active IP Right Cessation
- 1999-01-08 DE DE69932702T patent/DE69932702T2/de not_active Expired - Lifetime
- 1999-01-08 EP EP06016549A patent/EP1736170A3/de not_active Withdrawn
- 1999-01-08 ES ES99900567T patent/ES2270575T3/es not_active Expired - Lifetime
- 1999-01-08 AT AT99900567T patent/ATE335501T1/de active
- 1999-01-08 PT PT99900567T patent/PT1044014E/pt unknown
- 1999-01-08 GB GB0014295A patent/GB2347625A/en not_active Withdrawn
-
2006
- 2006-10-09 CY CY20061101443T patent/CY1105651T1/el unknown
-
2007
- 2007-03-27 US US11/691,798 patent/US8357372B2/en not_active Expired - Fee Related
-
2009
- 2009-04-24 JP JP2009107189A patent/JP2009161568A/ja active Pending
-
2013
- 2013-01-18 US US13/745,082 patent/US8992940B2/en not_active Expired - Fee Related
- 2013-05-14 JP JP2013101892A patent/JP2013151568A/ja not_active Withdrawn
-
2015
- 2015-02-23 US US14/628,717 patent/US20150165010A1/en not_active Abandoned
- 2015-07-02 JP JP2015133274A patent/JP2015166397A/ja active Pending
-
2017
- 2017-01-05 JP JP2017000474A patent/JP2017081977A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2017081977A (ja) | 2017-05-18 |
GB9800487D0 (en) | 1998-03-04 |
AU1978299A (en) | 1999-07-26 |
CA2317443A1 (en) | 1999-07-15 |
US20130345114A1 (en) | 2013-12-26 |
EP1736170A2 (de) | 2006-12-27 |
US20150165010A1 (en) | 2015-06-18 |
DE69932702T2 (de) | 2007-08-16 |
DK1044014T3 (da) | 2006-11-13 |
JP2002500194A (ja) | 2002-01-08 |
AU762478B2 (en) | 2003-06-26 |
ES2270575T3 (es) | 2007-04-01 |
GB2347625A (en) | 2000-09-13 |
WO1999034817A1 (en) | 1999-07-15 |
EP1736170A3 (de) | 2008-08-20 |
JP2009161568A (ja) | 2009-07-23 |
US7208155B1 (en) | 2007-04-24 |
EP1044014B9 (de) | 2007-01-03 |
EP1044014A1 (de) | 2000-10-18 |
NZ526218A (en) | 2004-10-29 |
JP2013151568A (ja) | 2013-08-08 |
DE69932702D1 (de) | 2006-09-21 |
US8357372B2 (en) | 2013-01-22 |
EP1044014B1 (de) | 2006-08-09 |
CA2317443C (en) | 2009-06-09 |
GB0014295D0 (en) | 2000-08-02 |
US8992940B2 (en) | 2015-03-31 |
CY1105651T1 (el) | 2010-12-22 |
PT1044014E (pt) | 2006-11-30 |
US20080206284A1 (en) | 2008-08-28 |
JP2015166397A (ja) | 2015-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE186834T1 (de) | Verwendung von wirksamen mengen von aktiven stoffen zur behandlung von mischhaut | |
ATE232082T1 (de) | Prophylaktische und therapeutische behandlung von haupt sensibilisierung und -reizung | |
DE69220679T2 (de) | Antibakterielles mittel und behandlung von gegenständen mit diesem | |
DE69426690T2 (de) | Behandlung von atrophischer Haut und Vagina | |
ATE62414T1 (de) | Mittel zur behandlung von herzerkrankungen. | |
DE69528602D1 (de) | Prophylaktische behandlung der allergischen kontaktdermatitis | |
DE69116380T2 (de) | Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit | |
DE68912195D1 (de) | Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis. | |
ATE335501T1 (de) | Mittel zur behandlung von allergischen oder überempfindlichkeitszuständen | |
DE3671365D1 (de) | Topische anwendung des 3-phenylacetylamino-2,6-piperidindions zur behandlung von hautfalten und hyperpigmentierung. | |
DE69902520D1 (de) | Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden | |
DE69305267T2 (de) | Zusammensetzung zur Behandlung von Mastitis und Metritis | |
DE69900774D1 (de) | Verwendung von topische präparationen mit glyceryl trinitrat und lanolin zur behandlung von erektilen funktionsstörungen | |
DE69300037T2 (de) | Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria. | |
ATE216884T1 (de) | Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden | |
DE68908445T2 (de) | Mittel zur Behandlung von Lebererkrankungen. | |
DE60043247D1 (de) | Verwendung von Peroxidlipiden zur Vorbeugung und/oder Behandlung von irritierenden Effekten eines Wirkstoffes | |
DE3881377T2 (de) | Mittel zur prophylaxe und behandlung von thrombocytopenie. | |
DE29507158U1 (de) | Mittel zur Behandlung und Pflege von Haaren und Kopfhaut | |
DE68914886D1 (de) | Mittel zur Behandlung von Raynaud's Krankheit. | |
DE29614217U1 (de) | Mittel zur Behandlung und Pflege von Haaren und Kopfhaut | |
DE3586949T2 (de) | Topische mittel zur verhuetung oder behandlung trockener haut. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1044014 Country of ref document: EP |